Table 4.
Comparison of uRPL patients receiving LMWH and LDA according to subsequent pregnancy outcome.
| uRPL Patients Receiving LMWH + LDA N = 63 |
Live Birth n = 52 |
Miscarriage n = 11 |
p-Value 1 |
|---|---|---|---|
| Age, median (Q1–Q3), years | 32.5 (4.6) | 34.1 (3.6) | 0.22 |
| Smoking history, n (%) | 19 (37) | 1 (9.1) | 0.15 |
| Ethnic group, n (%) | |||
| Caucasian | 49 (94) | 11 (100) | >0.99 |
| Maghrebin | 1 (1.9) | 0 (0) | |
| Afro-Caribbean | 2 (3.8) | 0 (0) | |
| Asian | 0 (0) | 0 (0) | |
| Body mass index, median (Q1–Q3) | 23.9 (4.2) | 23.9 (3.2) | 0.81 |
| Photosensivity, n (%) | 0 (0) | 0 (0) | |
| Joint pain, n (%) | 3 (5.8) | 1 (9.1) | 0.55 |
| Acrocyanosis, n (%) | 3 (5.8) | 0 (0) | >0.9 |
| Sicca syndrome, n (%) | 0 (0) | 0 (0) | |
| Livedo, n (%) | 4 (7.7) | 1 (9.1) | >0.9 |
| Raynaud’s phenomenon, n (%) | 4 (7.7) | 0 (0) | >0.9 |
| Thrombosis (arterial or venous), n (%) | 3 (5.8) | 1 (9.1) | 0.55 |
| Gestity, n (%) | 5.00(4.00, 6.00) | 6.00 (5.00, 6.50) | 0.050 |
| ≥6 | 18 (35) | 7 (64) | |
| <6 | 34 (65) | 4 (36) | |
| Pregnancy, n (%) | |||
| Live birth | 23 (44) | 6 (55) | 0.53 |
| Fetal death > 24 WG | 5 (9.6) | 1 (9.1) | >0.9 |
| Intrauterine growth restriction | 8 (15) | 1 (9.1) | >0.9 |
| Placental vascular pathology | 16 (31) | 2 (18) | 0.49 |
| HELLP or PE | 5 (9.6) | 0 (0) | 0.58 |
| Recurrent pregnancy loss only | 25 (48) | 4 (36) | 0.52 |
| ANA, n (%) | |||
| ≥1/80 | 23 (49) | 5 (55) | >0.9 |
| ≥1/160 | 14 (30) | 3 (33) | >0.9 |
| ≥1/320 | 10 (21) | 1 (11) | 0.67 |
| aPLA positivity according to Sydney criteria, n (%) | 15 (28) | 3 (27) | >0.9 |
| aPLA positivity according to updated criteria, n (%) | 4 (8) | 0 (0) | >0.9 |
1 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s chi-squared test. ANAs: Antinuclear antibodies; aPLAs: Antiphospholipid antibodies; HELLP: Hemolysis, Elevated Liver enzymes and Low Platelets; LDA: Low-dose aspirin; LMWH: Low-molecular-weight heparin; PE: Pre-eclampsia; WG: Weeks of gestation.